1031-107 The vascular endothelial growth factor +405 CC promotor polymorphism is associated with an impaired prognosis in patients with chronic heart failure: For the MERIT-HF study group  by Van der Meer, Peter et al.
JACC March 3, 2004 ABSTRACTS - Cardiac Function and Heart Failure  163A
Cardiac Function and Heart Failure
1031-104 The Angiotensin II Type Receptor A1166C 
Polymorphism and Heart Failure Outcomes
Yin Zheng, Anisha N. Shah, Maninder Bedi, Barry London, Dennis M. Mcnamara, 
University of Pittsburgh, Pittsburgh, PA
BACKGROUND The effects of angiotensin II are mediated by angiotensin II type 1
receptors (ATR1). A common polymorphism exists in the 3’ untranslated region of ATR1
(A1166C) and the C allele has been associated with vascular stiffness and risk of hyper-
tension. To date, few studies have evaluated the effect of this polymorphism on heart fail-
ure phenotype or outcomes. Therefore, we sought to evaluate the impact of the C allele
on heart failure progression through an examination of subjects in the GRACE (Genetic
Risk Assessment of Cardiac Events) database.
METHODS 432 subjects with heart failure due to systolic dysfunction (EF<0.45) were
enrolled between April 1996 and January 2001. Demographic information, New York
Heart Association Class, previous cardiovascular evaluation, and medical therapy were
recorded at entry, and subjects were followed prospectively to an end point of either
death or heart transplantation. Genomic DNA was extracted from peripheral blood and
genotyped. Baseline characteristics and outcomes were analyzed in the A1166C geno-
type subset.
RESULTS The mean age of the cohort was 55.8±12.0 years and the mean LVEF was
0.24±0.08. 84.3% of patients were treated with ACE inhibitors, 10.4% with angiotensin
receptor blockers, and 42.5% with β-blockers. 8.6% of patients were homozygous for the
C allele, 50.0% were homozygous for the A allele, and 41.4% were heterozygous (AC).
There were no differences in age, sex, race, etiology, and therapy among the 3 sub-
groups; The C allele was associated with lower NYHA Class (AA/AC/CC= 2.62± 0.61/
2.51 ± 0.63/ 2.43 ± 0.69, p= 0.035). The median follow-up time for all patients was 26.43
± 18.19 months (range, 1 to 62 months for patients alive and transplants); however, it was
not associated with poorer transplant-free survival (1 year percent survival AA/AC/CC =
79/79/86, 2-year=67/70/71, 3-year=58/59//61, p=0.36).
CONCLUSION In our heart failure population, the ATR1 C allele was associated with
lower NYHA class but did not affect transplant free survival. Despite the impact of this
polymorphism in vascular elasticity and hypertension, the ATR1 receptor polymorphism
does not appear to modulate clinical outcomes in heart failure.
1031-105 Effect of the Beta1Ser49Gly Polymorphism on 
Outcomes in Recent Onset Cardiomyopathy: Results 
From the IMAC Trial
Anisha N. Shah, Randall Starling, G. William Dec, Guillermo Torre-Amione, Alan Gass, 
Barry London, Dennis M. Mcnamara, for the IMAC Investigators, University of Pittsburgh, 
Pittsburgh, PA
Background: Ser49Gly is a polymorphism in the extra-cellular portion of the β1 receptor.
The Gly49 variant (G) has enhanced receptor down-regulation in vitro and in chronic
heart failure is associated with poorer outcomes in subjects not on beta blockers (bb), but
an enhanced response to bb therapy. We examined the impact of the Ser49Gly polymor-
phism in recent-onset cardiomyopathy (ROCM) though an analysis of subjects in the
Intervention in Myocarditis and Acute Cardiomyopathy Trial (IMAC).
Methods: 60 patients with ROCM (35M/25F, age 43±12, EF 0.25± 0.08, < 6 mo of symp-
toms) were genotyped for the β1Ser49Gly polymorphism. Patients were followed for two
years or an end point of death or transplantation. LVEF was reassessed by nuclear scan
at 6 and 12 months. Subjects heterozygous (SG, n=15) and homozygous for G (GG,
n=1) were grouped (group 1, n=16) and event-free survival compared with SS subjects
(group 2, n=44). Analysis was repeated in the subset of patients not on bb at entry
(n=47).
Results: The demographics and baseline therapy were similar between groups. The EF
at 12 mo follow up was 0.42± 0.14 and was similar between groups. The 1 and 2 year
event free survival for the entire cohort was 92 and 88%. The presence of Gly49 was
associated with more severe disease at presentation, but this was primarily in subjects
not on bb therapy (higher NYHA, p=0.05, lower sys BP, p=0.008, lower MVO2, p=0.07).
Consistent with these differences, group 1 subjects had a significantly poorer outcome
than group 2 (1 and 2 year event-free survival: group 1= 81%/75%; group 2=95%/93%,
p=0.04). No events were seen in subjects on bb at entry.
Conclusions: In subjects with ROCM, the β149Gly receptor variant is associated with
more functional limitations at presentation and poorer event free survival during follow-
up. The effect of the β1 variant on outcomes and the ability of β-blocker therapy to dimin-
ish its impact suggests the β1 receptor plays a crucial role in the early pathogenesis of
dilated cardiomyopathy and in the therapeutic efficacy of beta blockers.
1031-106 Real-Time Volume-Rendered Transthoracic Three-
Dimensional Echocardiography for Neonatal Heart 
Disease
Pierre C. Wong, Hui Gao, Mark S. Sklansky, Childrens Hospital Los Angeles, Los 
Angeles, CA, Keck School of Medicine, University of Southern California, Los Angeles, 
CA
Background: Little information exists about the use and effectiveness of volume-ren-
dered three-dimensional echocardiography (3DE) in the neonatal population. Because a
significant proportion of congenital heart disease (CHD) is diagnosed in neonates, and
echocardiography is the primary diagnostic modality, we sought to determine whether
real-time 3DE can effectively evaluate neonatal heart disease.
Methods: Using a new real-time 3DE system (Sonos 7500, Philips Medical Systems)
equipped with a two-dimensional (2D) matrix 2-4 MHz transthoracic probe, we performed
37 studies in 34 neonates < 5 weeks of age (age 6.3±7.5 days, range 1-32 days; weight
3.1±0.8 kg, range 0.9-5.0 kg) with both normal anatomy (2) and a wide variety of CHD,
including: arterial malposition (AM) (12), single ventricle (8), atrial or ventricular septal
defects (VSD) (8), semilunar valve stenosis (3), Ebstein’s anomaly (1). Using standard
transthoracic windows, multiple volume datasets were acquired rapidly and displayed as
volume renderings, with subsequent interactive cropping, reorientation and review offline.
Image diagnostic quality was compared to corresponding 2D images.
Results: Acquisition time per dataset ranged between 2-7 seconds. Despite small
patient size, variable chest wall contact, and rapid heart rates, image quality of 3D vol-
ume datasets compared favorably to corresponding 2D images in 34/37 studies (92%),
demonstrating all major abnormalities with acceptable resolution. Harmonic imaging sig-
nificantly enhanced image quality in 16/37 pts (43%). In 8/37 studies (2%)—5 AM, 1
Ebstein’s, 1 single ventricle (with AM), 1 VSD—3DE contributed new information to that
already provided by 2D imaging. It was especially useful in elucidating the geometry and
ventriculo-arterial relationships of complex AMs.Conclusions: Real-time volume-ren-
dered 3DE can be performed rapidly and effectively in neonates. While 2D provides
excellent imaging sufficient for most neonatal CHD, 3DE delivers additive value in
selected lesions, particularly complex AMs. Harmonic imaging appears to be useful in
improving image quality of neonatal real-time 3D volume-rendered displays.
1031-107 The Vascular Endothelial Growth Factor +405 CC 
Promotor Polymorphism Is Associated With an 
Impaired Prognosis in Patients With Chronic Heart 
Failure: For the MERIT-HF Study Group
Peter Van der Meer, Rudolf A. De Boer, Hazel L. White, Alistair S. Hall, Hans Hillege, Dirk 
J. Van Veldhuisen, University Hospital Groningen, Groningen, The Netherlands, 
University of Leeds, Leeds, United Kingdom
Background
Vascular endothelial growth factor (VEGF) causes angiogenesis, which may limit
ischemia and may be beneficial in Chronic Heart Failure (CHF). Recent reports have
shown that a common polymorphism at + 405 of the VEGF gene is related to VEGF pro-
tein production, while another common polymorphism at - 460 does not affect VEGF pro-
tein levels. Effects of these polymorphisms on outcome in CHF are unknown.
Methods
VEGF promoter polymorphisms +405 and -460 were examined by using sequence-spe-
cific primer-PCR in 600 patients enrolled in MERIT-HF. A risk-ratio (RR) for each geno-
type was calculated using the combined endpoint of all cause mortality or hospitalisation
(time to first event)
Results
The presence of the +405 CC genotype (n=84, 14%) was associated with a significant
worse outcome on the combined endpoint, RR=1.68; 95% confidence intervals (CI), 1.05
-2.68 (P=0.03). This remained statistically significant after adjustment for conventional
risk factors and study medication (metoprolol CR/XL or placebo). On the other hand, the
-460 polymorphism was not significantly associated with an altered prognosis (p=0.84).
Conclusion
These results indicate that the VEGF +405 CC genotype, which is related to lower VEGF
levels, is associated with an impaired outcome in patients with CHF. In contrast, the
VEGF -460 polymorphism, which is not associated with altered VEGF protein levels, did
not affect the prognosis.
1031-108 The Role of a Common Adenosine Monophosphate 
Deaminase-1 Polymorphism in Outcome of Ischemic 
and Nonischemic Heart Failure
Matthew J. Kolek, John F. Carlquist, Surai Thaneemit-Chen, Bryant M. Whiting, Benjamin 
D. Horne, Joseph B. Muhlestein, Philip Lavori, Jeffrey L. Anderson, LDS Hospital, Salt 
Lake City, UT
Background: A common, nonsense variant of the adenosine monophosphate deami-
nase (AMPD)-1 gene (C34T) results in enzymatic inactivity and may increase adenosine
in skeletal and cardiac muscle and confer cardioprotection through ischemic precondi-
tioning.
Methods: We hypothesized that AMPD1 carriers with ischemic CHF in the Beta-Blocker
Evaluation of Survival Trial (BEST) might have a relative survival advantage. Patient DNA
samples (N=1038) of which 58% (n=605) had ischemic CHF, 42% (n=433) non-ischemic
etiology CHF and 20% (n=206) patients were Black. Patient follow-up for all-cause mor-
tality averaged 2.0 y. DNA samples were provided by the Beta-Blocker Evaluation of Sur-
vival Trial the BEST DNA Bank co-sponsored by the National Heart, Lung, and Blood
